Matthias-Lorenz-Research-Award

Matthias-Lorenz-Research-Award

The Matthias-Lorenz-Research-Award is donated by PharmaCept GmbH for the first time in 2012 and is endowed with € 3,000. Now this award will be held every two years to scientists for outstanding work in the field of locoregional tumor therapy.

Matthias-Lorenz-Research-Award 2017

On 13 January 2017, the Matthias-Lorenz-Research-Award was awarded for the third time at the Dreiländertagung of the German, Austrian and Swiss Societies for Interventional Radiology (IROS). The winner, Dr. med. T. Gruber-Rouh, Senior Physician at the Institute for Diagnostic and Interventional Radiology University of Frankfurt / M received the € 3,000 prize at the PharmaCept Symposium.

The title of her publication is:
Transarterial chemoembolization of unrespectable systemic chemotherapy-refractory liver metastasis from colorectal cancer: Long-term results over a 10-year period
Congratulations to Dr. Tatjana Gruber-Rouh and wish her continued success!


Prof. Dr. Thomas Vogl, Director of radiological Institute of University Frankfurt/M, Dr. Tatjana Gruber-Rouh, Matthias-Lorenz Research Award Winner, Dr. Jürgen Ebert, CEO PharmaCept GmbH

Matthias-Lorenz-Research-Award 2014

Congratulation!
For the second time we granted a study with the Matthias-Lorenz-research-award. The awardee got his award during the German cancer congress in Berlin.

The title of publication is: “Hepatic arterial infusion of temsirolimus inhibits tumor growth of colorectal rat liver metastases even after a growth stimulating procedure like liver resection”

matthiaslorenzforschungspreis2014Dr. Jürgen Ebert , GF PharmaCept GmbH, Dr. J. Sperling, Uni Göttingen, Prof. Dr. Boese-Landgraf, CA Klinikum Chemnitz
 
 
 
 
 
 
 
 
 
 
 
 
 

Matthias-Lorenz-Research-Award 2012

For the first time PharmaCept GmbH initiated a research award in 2012.
24 research groups submitted their publications and results. We would like to thank every applicant for their interest and efford.

The winner of the research award is a interdisciplinary research group* from Munich (TU Munich), submitted by Dr. R. Braren.

The title of the study is:
“Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization”


 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. Jürgen Ebert, CEO PharmaCept, Dr. Rickmer Braren, Matthias-Lorenz Research Award Winner, Prof. Dr. Boese-Landgraf, clinical centre Chemnitz
(Quelle: M. Schuck, Weimar)

*) Rickmer Braren, Jennifer Altomonte, Marcus Settles, Frauke Neff, Irene Esposito, Oliver Ebert, Markus Schwaiger, Ernst Rummeny, Andreas Steingoetter